Iovance Biotherapeutics (FRA:2LB) EV-to-EBIT : -4.37 (As of Jun. 06, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Iovance Biotherapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Iovance Biotherapeutics's Enterprise Value is €1,889.83 Mil. Iovance Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-432.01 Mil. Therefore, Iovance Biotherapeutics's EV-to-EBIT for today is -4.37.

The historical rank and industry rank for Iovance Biotherapeutics's EV-to-EBIT or its related term are showing as below:

FRA:2LB' s EV-to-EBIT Range Over the Past 10 Years
Min: -8.9 Med: -3.73 Max: -1.2
Current: -4.4

During the past 13 years, the highest EV-to-EBIT of Iovance Biotherapeutics was -1.20. The lowest was -8.90. And the median was -3.73.

FRA:2LB's EV-to-EBIT is ranked worse than
100% of 424 companies
in the Biotechnology industry
Industry Median: 9.96 vs FRA:2LB: -4.40

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Iovance Biotherapeutics's Enterprise Value for the quarter that ended in Mar. 2024 was €3,365.77 Mil. Iovance Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-432.01 Mil. Iovance Biotherapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -12.84%.

Iovance Biotherapeutics EV-to-EBIT Historical Data

The historical data trend for Iovance Biotherapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iovance Biotherapeutics EV-to-EBIT Chart

Iovance Biotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-15.49

-23.81

-7.48

-2.04

-4.08

Iovance Biotherapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															-1.98	-3.30	-1.98	-4.08	-8.29

Competitive Comparison of Iovance Biotherapeutics's EV-to-EBIT

For the Biotechnology subindustry, Iovance Biotherapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Iovance Biotherapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Iovance Biotherapeutics's EV-to-EBIT falls into.

Iovance Biotherapeutics EV-to-EBIT Calculation

Iovance Biotherapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	1889.834	/	-432.009
	=	-4.37

Iovance Biotherapeutics's current Enterprise Value is €1,889.83 Mil.
Iovance Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-432.01 Mil.

Iovance Biotherapeutics (FRA:2LB) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Iovance Biotherapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-432.009	/	3365.7693
	=	-12.84 %

Iovance Biotherapeutics's Enterprise Value for the quarter that ended in Mar. 2024 was €3,365.77 Mil.
Iovance Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-432.01 Mil.

Iovance Biotherapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Iovance Biotherapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Iovance Biotherapeutics (FRA:2LB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iovance Biotherapeutics Inc (FRA:2LB) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

IOVA:USA

Address

825 Industrial Road, Suite 400, San Carlos, CA, USA, 94070

Website

https://www.iovance.com

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approval and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Iovance Biotherapeutics (FRA:2LB) Headlines

No Headlines